SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-28
DOI
10.3389/fimmu.2021.627568
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A new coronavirus associated with human respiratory disease in China
- (2020) Fan Wu et al. NATURE
- RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak
- (2020) Liangjun Chen et al. Emerging Microbes & Infections
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
- (2020) Alba Grifoni et al. CELL
- Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019
- (2020) Juanjuan Zhao et al. CLINICAL INFECTIOUS DISEASES
- Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
- (2020) Ling Ni et al. IMMUNITY
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Factors associated with hospital admission for COVID-19 in HIV patients
- (2020) Antonio Di Biagio et al. AIDS
- Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro
- (2020) Ka-Tim Choy et al. ANTIVIRAL RESEARCH
- COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy
- (2020) Leonardo Calza et al. INFECTION
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
- (2020) Julian Braun et al. NATURE
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
- (2020) Nina Le Bert et al. NATURE
- Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’
- (2020) Enrico Lavezzo et al. NATURE
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
- (2020) Jose Mateus et al. SCIENCE
- SARS‐CoV‐2 and HIV coinfection: clinical experience from Rhode Island, United States
- (2020) Katrina M Byrd et al. Journal of the International AIDS Society
- Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
- (2020) Carolyn Rydyznski Moderbacher et al. CELL
- Outcomes Among HIV-Positive Patients Hospitalized With COVID-19
- (2020) Savannah Karmen-Tuohy et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity
- (2020) Marie Kroemer et al. JOURNAL OF INFECTION
- Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19
- (2020) Yanchun Peng et al. NATURE IMMUNOLOGY
- SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
- (2020) Annika Nelde et al. NATURE IMMUNOLOGY
- T-cell receptor transfer for boosting HIV-1-specific T-cell immunity in HIV-1-infected patients
- (2016) Christiane Mummert et al. AIDS
- HIV Status, Burden of Comorbid Disease, and Biomarkers of Inflammation, Altered Coagulation, and Monocyte Activation
- (2012) K. A. Armah et al. CLINICAL INFECTIOUS DISEASES
- Relationship between T Cell Activation and CD4+T Cell Count in HIV‐Seropositive Individuals with Undetectable Plasma HIV RNA Levels in the Absence of Therapy
- (2007) Peter W. Hunt et al. JOURNAL OF INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More